Panelists discuss how the current topical standard of care has evolved from traditional topical steroids developed in the 1960s to include newer nonsteroidal options like ruxolitinib (Janus kinase [JAK] inhibitor), roflumilast (phosphodiesterase-4 [PDE4] inhibitor), and tapinarof (aryl hydrocarbon receptor agonist), with steroids now serving as bridge treatments rather than long-term maintenance therapy.
Panelists discuss how atopic dermatitis presents differently across pediatric age groups. Infants show lesions on cheeks and extensor surfaces, whereas older children develop more typical flexural patterns. They also discuss how the condition significantly impacts the quality of life for patients and caregivers through sleep disruption, school performance issues, and ongoing parental stress.
Panelists discuss how thiamidol has shown real-world success in treating stippled postinflammatory hyperpigmentation (PIH) from acne picking when applied 4 times daily alongside retinoids and chemical peels, with the key being proper product layering and selecting adherent patients who can manage multiple daily applications.
Panelists discuss how nonhydroquinone agents, such as thiamidol, demonstrate excellent tolerability profiles in data from head-to-head studies and how combination therapies including chemical peels, picosecond lasers, microneedling with transdermal delivery, and oral tranexamic acid can be used as adjunctive treatments for stubborn melasma cases that plateau with topical therapy alone.
If passed, the Safe Step Act could reduce treatment delays by prohibiting step therapy for FDA-labeled, guideline-supported agents.
Panelists discuss how OX40-pathway therapies may serve as first-line treatments after topicals due to their promising efficacy and safety profiles, though questions remain about optimal patient selection, long-term safety, and predictive biomarkers.
Panelists discuss how multiple OX40 pathway–targeted drugs are in development, including rocatinlimab (anti-OX40, cell depleting) and amlitelimab (anti-OX40L, nondepleting), both showing promising phase 2/3 results with potential for sustained responses.
Amy Lewis, MD, integrates Glo2Facial into her practice to enhance patient relationships and promote early skin health through innovative aesthetic treatments.
Panelists discuss how dermatologists play a vital role in helping patients navigate the overwhelming variety of skin care products by emphasizing simple, gentle, and fragrance-free routines focused on cleansing, moisturizing, and protection—highlighting that consistency and patience are key to restoring skin barrier health, especially in sensitive skin. They also stress that effective skin care does not require expensive products, and tailoring regimens with evidence-supported ingredients like polymeric surfactants and lipid-based moisturizers improves adherence and outcomes.
Panelists discuss a recent study showing that once-daily application of a moisturizer over 4 weeks significantly improved skin hydration, texture, and radiance, with benefits persisting even after discontinuation—highlighting the lasting impact of well-formulated products on skin barrier health. They also emphasize the importance of tailoring moisturizer types, such as lighter gels for acne-prone skin and richer creams for dry or compromised skin, to address specific patient needs and sensitivities for optimal outcomes.
Panelists discuss recent studies on advanced moisturizers that not only provide immediate hydration but also stimulate the skin’s natural production of key proteins and lipids, such as aquaporin-3 and filaggrin, leading to sustained improvements in barrier function and skin health—benefits that are particularly important for individuals with sensitive or compromised skin and support the need for consistent, targeted moisturizing in clinical care.
Discover how the Glo2Facial revolutionizes aesthetic dermatology with innovative skin oxygenation and customizable treatments for radiant, youthful skin.
A late-breaking EADV presentation revealed that ritlecitinib significantly improved outcomes in patients with multiple forms of scarring alopecia.
The biologic’s less frequent injections could ease logistical and emotional strain for patients with atopic dermatitis and their families.
Lipella Pharmaceuticals' LP-10 shows promise as a targeted treatment for OLP, offering safety and efficacy in recent trials, according to Michael Chancellor, MD.
Panelists discuss how hydroquinone’s safety concerns including ochronosis and irritation necessitate the use of alternative tyrosinase inhibitors such as thiamidol, cysteamine, kojic acid, and lotus sprout extract, which offer better tolerability and can provide an overall skin evening and glow that patients desire.
Panelists discuss how treatment selection for melasma should begin with topical regimens including lightening agents, retinoids, and sun protection before considering procedures, emphasizing patient adherence and the appropriate use of hydroquinone and triple combination therapies as gold standard treatments despite some tolerability concerns.
Panelists discuss how OX40 pathway–targeted therapies may benefit specific patient subsets with particular immunologic profiles and could potentially modify the disease course when used early, although patient selection criteria remain unclear.
Panelists discuss how the OX40-OX40L costimulatory pathway represents a promising upstream target for atopic dermatitis treatment by modulating T-cell survival, expansion, and memory formation rather than targeting downstream cytokines. Panelists discuss how targeting the OX40-OX40L pathway could potentially provide broader therapeutic effects across multiple T-cell subsets and offer more durable responses than current cytokine-specific or JAK inhibitor approaches.
Brian Kim, MD, FAAD, explores the transformative role of neuroimmunology in dermatology, urging a shift towards systems-level therapeutic strategies.
Brian Kim, MD, FAAD, explores the Cell Symposia: Neuro-immune Axis, highlighting neuroimmunology's impact on dermatology and systemic medicine.
Panelists discuss recent research highlighting the benefits of polymeric surfactant–based cleansers, which preserve key skin barrier functions and the microbiome while providing a gentle yet effective cleansing experience that supports patient adherence—especially important for sensitive skin conditions like eczema and rosacea—and emphasize the complementary role of moisturizers rich in lipids and humectants to restore and maintain barrier health across diverse patient needs.
Panelists discuss a recent study demonstrating that cleansers formulated with hydrophobically modified polymers significantly improve skin condition and patient comfort in individuals with clinically diagnosed sensitive skin, highlighting their ability to cleanse gently while supporting barrier repair without disrupting the skin’s microbiome.
Trial data show up to 30% of patients achieved complete response and 70% demonstrated some benefit from treatment.
Lisa Espinoza, MD, highlights the importance of patient education and tailored HA filler treatments for achieving natural cosmetic results.
Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, shares how Apex Skin is improving trial adherence through bilingual staff, modernizing operations with digital tools, and strengthening community partnerships.
ORKA-001 builds on the proven success of existing IL-23 inhibitors used in psoriasis treatment.
Lisa Espinoza, MD, discusses key insights from Allergan's Hyaluronic Acid Injectable Fillers Report, highlighting patient satisfaction and evolving aesthetic trends.
Explore insights from Renata Block DMSc, MMS, PA-C, and James Del Rosso, DO, on interpreting clinical trial data in dermatology for enhanced patient care and outcomes.
Panelists discuss how melasma diagnosis requires identifying specific location patterns, absence of scale, avoidance of eyelid areas, and using Wood lamp examination to differentiate between superficial and deep melasma while distinguishing it from other pigmentary conditions such as postinflammatory hyperpigmentation and solar lentigines.
